Get the Stockscreener App
0.512
0.41%
-0.0021
Applied Therapeutics Inc stock is traded at $0.512, with a volume of 605.35K.
It is down -0.41% in the last 24 hours and up +7.81% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.5141
Open:
$0.5136
24h Volume:
605.35K
Relative Volume:
0.32
Market Cap:
$73.73M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.3793
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
+6.87%
1M Performance:
+7.81%
6M Performance:
-3.40%
1Y Performance:
-90.86%
1-Day Range:
$0.5023
$0.52
1-Week Range:
$0.4713
$0.53
52-Week Range:
$0.295
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.512 | 72.01M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-02-24 | Downgrade | UBS | Buy → Neutral |
| Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-31-24 | Initiated | William Blair | Outperform |
| Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-22-24 | Initiated | Leerink Partners | Outperform |
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
Applied Therapeutics Inc. Included in Top Momentum Scan2025 Historical Comparison & Verified Swing Trading Watchlist - thegnnews.com
Top chart patterns to watch in Applied Therapeutics Inc.Portfolio Gains Summary & Expert Approved Momentum Ideas - Newser
Relative strength of Applied Therapeutics Inc. in sector analysisEarnings Miss & Real-Time Volume Trigger Notifications - Newser
Forecasting Applied Therapeutics Inc. price range with options dataMarket Sentiment Report & Daily Momentum Trading Reports - Newser
Using AI based signals to follow Applied Therapeutics Inc.July 2025 Decliners & Verified Swing Trading Watchlists - Newser
Price momentum metrics for Applied Therapeutics Inc. explained2025 Market Trends & Weekly High Return Stock Forecasts - Newser
Chart based exit strategy for Applied Therapeutics Inc.Market Trend Summary & Consistent Profit Trade Alerts - Newser
Will earnings trigger a reversal in Applied Therapeutics Inc.2025 Pullback Review & Free Weekly Chart Analysis and Trade Guides - Newser
Applied Therapeutics (NASDAQ:APLT) Posts Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
What is William Blair's Estimate for APLT Q3 Earnings? - MarketBeat
Combining machine learning predictions for Applied Therapeutics Inc.Weekly Trend Summary & Weekly Breakout Watchlists - Newser
What is William Blair’s Estimate for APLT Q3 Earnings? - Defense World
Why Applied Therapeutics Inc. stock attracts strong analyst attentionOil Prices & Verified Swing Trading Watchlist - Newser
Does Applied Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Breakouts & High Conviction Trade Alerts - Newser
Applied Therapeutics Inc. Stock Support and Resistance Levels You Should KnowPortfolio Value Report & Low Risk High Win Rate Stock Picks - Newser
Applied Therapeutics Reports Q2 Loss - AOL.com
Is Applied Therapeutics Inc. stock bottoming outJuly 2025 Pullbacks & Stepwise Trade Signal Implementation - Newser
Trend analysis for Applied Therapeutics Inc. this week2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - Newser
Multi asset correlation models including Applied Therapeutics Inc.Weekly Trade Recap & Consistent Income Trade Recommendations - Newser
Applying Elliott Wave Theory to LanzaTech Global Inc.July 2025 Institutional & Safe Capital Investment Plans - Newser
Has Applied Therapeutics Inc. found a price floor2025 Price Momentum & Free Expert Approved Momentum Trade Ideas - Newser
Applied Therapeutics Granted Nasdaq Compliance Extension - MSN
Long term hold vs stop loss in Applied Therapeutics Inc.July 2025 Analyst Calls & Advanced Technical Analysis Signals - Newser
Applied Therapeutics shares fall 2.54% intraday after reporting unaudited estimate of total stockholders' equity. - AInvest
Applied Therapeutics Receives Nasdaq Compliance Extension, Considers Reverse Stock Split - AInvest
Applied Therapeutics Inc.’s Beta Climbs After Market VolatilityJuly 2025 Macro Moves & Trade Opportunity Analysis Reports - sundaytimes.kr
What’s Applied Therapeutics Inc.’s historical returnRecession Risk & Growth Oriented Trade Recommendations - thegnnews.com
Momentum Indicator Shows Bearish Divergence in Applied Therapeutics Inc.Market Activity Summary & Fast Moving Trade Plans - newsyoung.net
Applied Therapeutics Posts Q2 GAAP EPS of -$0.15, Beats by $0.01, with $30.4M in Cash and Cash Equivalents - AInvest
Applied Therapeutics Advances Pipeline Amid Financial Challenges: Q2 Earnings Breakdown - AInvest
Applied Therapeutics Advances Pipeline Amid Financial Challenges - TipRanks
Applied Therapeutics Advances CMT-SORD Program with FDA Meeting Scheduled for 2025 - SSBCrack
Applied Therapeutics Reports Second Quarter 2025 Financial Results | APLT Stock News - GuruFocus
Applied Therapeutics reports Q2 EPS (15c), consensus (16c) - TipRanks
Applied Therapeutics, Inc. SEC 10-Q Report - TradingView
Applied Therapeutics Reports Second Quarter 2025 Financial Results - The Manila Times
Applied Therapeutics, Inc. Advances CMT-SORD Program and Schedules FDA Meeting for Govorestat, Reports Second Quarter Financial Results - Quiver Quantitative
Applied Therapeutics says unaudited estimate of total stockholders' equity as of June 30 is about $17.4 mln - MarketScreener
Applied Therapeutics Says Unaudited Estimate Of Total Stockholders’ Equity As Of June 30 Is About $17.4 Mln - TradingView
Analyzing Applied Therapeutics Inc. with risk reward ratio chartsFree Investment Plan With Growth Optimization - Newser
Applied Therapeutics Inc. stock momentum explainedSwing Trade Planning with Consistent Setup - Newser
What institutional flow reveals about Applied Therapeutics Inc.AI Volatility Forecast and Risk Monitor - Newser
How Applied Therapeutics Inc. stock reacts to Fed policy changesInvestment Position Summary with Timeframe Forecast - Newser
Bank of New York Mellon Corp Increases Stock Holdings in Applied Therapeutics Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics (APLT) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Sector Rotation Brings Applied Therapeutics Inc. Into FocusTop Gaining Low Risk Assets - beatles.ru
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Applied Therapeutics Inc Stock (APLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Funtleyder Leslie D. | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
14,502 |
6,381 |
390,459 |
| Chinoporos Constantine | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
447 |
197 |
271,436 |
| Funtleyder Leslie D. | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
22,950 |
14,000 |
404,961 |
| Perfetti Riccardo | Chief Medical Officer |
Feb 06 '25 |
Sale |
0.61 |
86,078 |
52,508 |
900,775 |
| Chinoporos Constantine | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
28,117 |
17,151 |
271,883 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):